Research within the Multiscale Imaging group focuses on new types of contrast agents for multiple types of imaging such as 1H and 19F magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), single photon emission CT (SPECT), bioluminescence, ultrasound, optoacoustics and fluorescence, simultaneously.
The particles contain liquid perfluorocarbons with a metal chelate in a polymer matrix, resulting in a unique structure that we are actively studying through different types of NMR and even Small Angle Neutron Scattering (SANS), among others.
We are also developing the nanoparticles to comprehensively monitor modern personalised medicine, such as cell therapies, targeted therapies and theranostics. We are involved with all aspects of this work, including label development and formulation for human (GMP) and preclinical use, cell handling and labeling, in vivoanimal models, imaging, development for clinical application and upscaling production. The work is inherently multidisciplinary, and we work with immunologists, chemists, physicists and physicians, with a clinical trial with melanoma patients in progress.